Asset profile
APNmAb005
Monoclonal antibody
Evidence outlook · program status
On hold, as a strategic decision by the sponsor
APNmAb005 is APRINOIA Therapeutics' conformation-selective anti-tau monoclonal antibody, its lead therapeutic candidate for Alzheimer's disease and other tauopathies. APRINOIA's F-1 registration statement states that the Phase 1 study is paused, not recruiting, because of a reprioritization of resources, which is a hold rather than a termination. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
67 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 67 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| APNmAb005: this drug | Phase 1 | Monoclonal antibody | Tau (monoclonal antibody) | ||
| NIO752 | Phase 3 | RNA / oligonucleotide | Tau (monoclonal antibody) | ||
| Etalanetug | Phase 2/3 | Monoclonal antibody | Tau (monoclonal antibody) | ||
| AADvac1 | Phase 2 | Vaccine | Tau (monoclonal antibody) | ||
| Bepranemab | Phase 2 | Monoclonal antibody | Tau (monoclonal antibody) | ||
| BMS-986446 | Phase 2 | Monoclonal antibody | Tau (monoclonal antibody) | ||
| ACI-35.030 | Phase 1/2 | Vaccine | Tau (monoclonal antibody) | ||
| VY7523 | Phase 1/2 | Monoclonal antibody | Tau (monoclonal antibody) | ||
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA | ||
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Lecanemab (Leqembi) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Xanomeline / Trospium Chloride (Cobenfy) | Approved | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | ||
| ACP-204 | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| AR1001 | Phase 3 | Small molecule | PDE5 |
…and 52 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.